A Roche release and an Endpoint Arena report match the TAISHAN-302 result as the same drug-development event dated 13 September. The sources say the Tam-Peli and topotecan comparison was presented at WCLC 2026. With no detailed scientific publication in the pool, the card stays with the announcement's identity, scope and publication status; it makes no clinical-effect or treatment recommendation.
Roche and Endpoint Arena publish the TAISHAN-302 result as the same development dated 13 September. Roche's page announces the Tam-Peli and topotecan comparison as a presentation at WCLC 2026. Endpoint Arena's drug-development calendar also reports the event date, study name and same comparison. The sources therefore match on the event identity and timing, while the detailed announcement comes from Roche, the study sponsor.[1], [2]
Roche's announcement identifies Tam-Peli as a B7-H3-directed antibody-drug conjugate studied in relapsed small-cell lung cancer. The source pool confirms the TAISHAN-302 name and its comparison with topotecan. This card does not analyze how the medicine was administered, how participants were selected or the magnitude of the finding. Those details cannot be assessed reliably here without a direct scientific publication.[1]
The sources say the TAISHAN-302 result was presented at WCLC 2026; the pool contains no detailed scientific publication. This report therefore establishes that a new conference announcement exists and identifies the medicines compared. It does not determine the result's place in clinical practice, its applicability to different patient groups or its safety balance. Those questions require detailed scientific publication and independent assessment.[1], [2]
